This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Physical health check and laboratory monitoring for patients with bipolar disorder

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • all patients with bipolar disorder should have an annual physical health review, normally in primary care, to ensure that the following are assessed each year:
    • lipid levels, including cholesterol in all patients over 40 even if there is no other indication of risk
    • plasma glucose levels
    • weight
    • smoking status and alcohol use
    • blood pressure

  • guidance for investigations in addition to annual checks described above:
    • thyroid function tests
      • for patients on lithium therapy - at start and every function 6 months; more often if evidence of deterioration
    • liver function tests
      • for patients on either valproate or carbamazepine - at start and at 6 months
    • renal function tests
      • for patients on lithium
        • at start and every 6 months; more often if there is evidence of deterioration or the patient starts taking drugs such ACE inhibitors, diuretics or NSAIDs
    • full blood count
      • if on lithium therapy - only if clinically indicated
      • if on either valproate or carbamazepine - at the start and at 6 months
    • blood glucose
      • if on antipsychotic therapy - at start and at 3 months (and at 1 month if taking olanzapine); more often if there is evidence of elevated levels
    • lipid profile
      • if on antipsychotic therapy - at start and at 3 months; more often if there is evidence of elevated levels
    • prolactin - if on risperidone then measure at start and if symptoms of hyperprolactinaemia develop
    • ECG - measure at start if on either antipsychotics or lithium if there are risk factors for or existing cardiovascular disease
    • weight
      • if on antipsychotic therapy - at start and every 3 months for first year; more often if the patient gains weight rapidly
      • if on lithium therapy - at start and when needed if the patient gains weight rapidly
      • if on valproate therapy - at start and at 6 months if the patient gains weight rapidly
      • if on carbamazepine therapy - at start and at 6 months if the patient gains weight rapidly
    • serum levels of drug
      • lithium - 1 week after initiation and 1 week after every dose change until levels stable, then every 3 months
      • valproate - Only if there is evidence of ineffectiveness, poor adherence or toxicity
      • carbamazepine - every 6 months

Reference:

  1. NICE (July 2006). Bipolar disorder.

 

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.